Answer
Jan 22, 2026 - 01:02 PM
Yes, Valdoxan is the first antidepressant with a non-monoaminergic component, meaning it does not primarily target traditional monoamine neurotransmitters like serotonin, norepinephrine, or dopamine. This may provide an alternative for patients who have not had success with standard antidepressants, offering a new approach to treating depression.
